Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod in moderately to severely active ulcerative colitis
NCT01647516Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2012
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 2 trial of ozanimod in ulcerative colitis (UC), sponsored by Celgene Corporation. Started Dec 2012; status: completed.
02
Drugs
ozanimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01647516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01647516.